Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy

被引:71
|
作者
Zile, Michael R. [1 ,2 ]
Abraham, William T. [3 ]
Weaver, Fred A. [4 ]
Butter, Christian [5 ]
Ducharme, Anique [6 ]
Halbach, Marcel [7 ]
Klug, Didier [8 ]
Lovett, Eric G. [9 ]
Mueller-Ehmsen, Jochen [10 ]
Schafer, Jill E. [11 ]
Senni, Michele [12 ]
Swarup, Vijay [13 ]
Wachter, Rolf [14 ,15 ]
Little, William C. [16 ]
机构
[1] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA
[2] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA
[3] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA
[4] Univ So Calif, Keck Sch Med, Div Vasc Surg & Endovasc Therapy, Los Angeles, CA 90033 USA
[5] Immanuel Heart Ctr Bernau, Med Sch Brandenburg, Dept Cardiol, Bernau, Germany
[6] Univ Montreal, Montreal Heart Inst, Montreal, PQ H3C 3J7, Canada
[7] Univ Hosp Cologne, Dept Internal Med 3, Cologne, Germany
[8] Univ Hosp, Dept Cardiol A, Lille, France
[9] CVRx Inc, Dept Res, Minneapolis, MN USA
[10] Asklepios Klin Altona, Dept Med, Hamburg, Germany
[11] NAMSA Inc, Dept Stat, Minneapolis, MN USA
[12] Osped Papa Giovanni XXIII, Cardiovasc Dept, Bergamo, Italy
[13] Arizona Heart Hosp, Dept Electrophysiol, Phoenix, AZ USA
[14] Univ Med Gottingen, Clin Cardiol & Pneumol, Gottingen, Germany
[15] German Cardiovasc Res Ctr DZHK, Gottingen, Germany
[16] Univ Mississippi, Div Cardiovasc, Med Ctr, Jackson, MS 39216 USA
关键词
Baroreflex; Heart failure; Resynchronization; Autonomic nervous system; Randomized controlled trial; INHIBITION; SYSTEM;
D O I
10.1002/ejhf.299
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsIncreased sympathetic and decreased parasympathetic activity contribute to heart failure (HF) symptoms and disease progression. Carotid baroreceptor stimulation (baroreflex activation therapy, BAT) results in centrally mediated reduction of sympathetic and increase in parasympathetic activity. Because patients treated with cardiac resynchronization therapy (CRT) may have less sympathetic/parasympathetic imbalance, we hypothesized that there would be differences in the response to BAT in patients with CRT vs. those without CRT. Methods and resultsNew York Heart Association (NYHA) Class III patients with an ejection fraction (EF) 35% were randomized (1 : 1) to ongoing guideline-directed medical and device therapy (GDMT, control) or ongoing GDMT plus BAT. Safety endpoint was system-/procedure-related major adverse neurological and cardiovascular events (MANCE). Efficacy endpoints were Minnesota Living with Heart Failure Quality of Life (QoL), 6-min hall walk distance (6MHWD), N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and HF hospitalization rate. In this sample, 146 patients were randomized (70 control; 76 BAT) and were 140 activated (45 with CRT and 95 without CRT). MANCE-free rate at 6 months was 100% in CRT and 96% in no-CRT group. At 6 months, in the no-CRT group, QoL score, 6MHWD, LVEF, NT-proBNP and HF hospitalizations were significantly improved in BAT patients compared with controls. Changes in efficacy endpoints in the CRT group favoured BAT; however, the improvements were less than in the no-CRT group and were not statistically different from control. ConclusionsBAT is safe and significantly improved QoL, exercise capacity, NTpro-BNP, EF, and rate of HF hospitalizations in GDMT-treated NYHA Class III HF patients. These effects were most pronounced in patients not treated with CRT.
引用
收藏
页码:1066 / 1074
页数:9
相关论文
共 50 条
  • [21] Cardiac resynchronization therapy with or without defibrillator in patients with heart failure
    Schrage, Benedikt
    Lund, Lars H.
    Melin, Michael
    Benson, Lina
    Uijl, Alicia
    Dahlstrom, Ulf
    Braunschweig, Frieder
    Linde, Cecilia
    Savarese, Gianluigi
    EUROPACE, 2022, 24 (01): : 48 - 57
  • [22] Impact of Ejection Fraction on the Clinical Response to Cardiac Resynchronization Therapy in Mild Heart Failure
    Linde, Cecilia
    Daubert, Claude
    Abraham, William T.
    Sutton, Martin St John
    Ghio, Stefano
    Hassager, Christian
    Herre, John M.
    Bergemann, Tracy L.
    Gold, Michael R.
    CIRCULATION-HEART FAILURE, 2013, 6 (06) : 1180 - 1189
  • [23] Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction? Justification for the ongoing KaRen project
    Donal, Erwan
    Lund, Lars
    Linde, Cecilia
    Daubert, Jean-Claude
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2010, 103 (6-7) : 404 - 410
  • [24] Exercise-Based Cardiac Rehabilitation Improves Exercise Capacity Regardless of the Response to Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Ejection Fraction
    Misumi, Kayo
    Nakanishi, Michio
    Miura, Hiroyuki
    Date, Ayumi
    Tokeshi, Tatsuo
    Kumasaka, Leon
    Arakawa, Tetsuo
    Nakao, Kazuhiro
    Hasegawa, Takuya
    Fukui, Shigefumi
    Yanase, Masanobu
    Noguchi, Teruo
    Kusano, Kengo
    Yasuda, Satoshi
    Goto, Yoichi
    CIRCULATION JOURNAL, 2022, 86 (01) : 49 - 57
  • [25] The efficacy and safety outcomes of cardiac resynchronization therapy in patients with heart failure in Thailand: Phramongkutklao experience
    Limprasert, Sarawuth
    Uerojanaungkul, Preecha
    Chantrarat, Thoranis
    JOURNAL OF ARRHYTHMIA, 2022, 38 (01) : 126 - 136
  • [26] Devices for Autonomic Regulation Therapy in Heart Failure With Reduced Ejection Fraction
    Wagner, Benjamin R.
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2018, 26 (01) : 43 - 49
  • [27] Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure
    Ghali, Jalal K.
    Boehmer, John
    Feldman, Arthur M.
    Saxon, Leslie A.
    Demarco, Teresa
    Carson, Peter
    Yong, Patrick
    Galle, Elizabeth G.
    Leigh, Jill
    Ecklund, Fred L.
    Bristow, Michael R.
    JOURNAL OF CARDIAC FAILURE, 2007, 13 (09) : 769 - 773
  • [28] Modeling the physiological roles of the heart and kidney in heart failure with preserved ejection fraction during baroreflex activation therapy
    Clemmer, John S.
    Pruett, W. Andrew
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2022, 323 (03): : H597 - H607
  • [29] Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction
    Kocabas, Umut
    Ergin, Isil
    Kivrak, Tarik
    Oztekin, Guelsuem Meral Yilmaz
    Tanik, Veysel Ozan
    Ozdemir, Ibrahim
    Demir, Fulya Avci
    Dogdus, Mustafa
    Sen, Taner
    Altinsoy, Meltem
    Ustundag, Songuel
    Urgun, Orsan Deniz
    Sinan, Umit Yasar
    Uygur, Begum
    Yeni, Mehtap
    Ozcalik, Emre
    ESC HEART FAILURE, 2023, 10 (06): : 3677 - 3689
  • [30] Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction
    Straw, Sam
    McGinlay, Melanie
    Witte, Klaus K.
    OPEN HEART, 2021, 8 (01):